Makimoto A - Search Results

1

Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults.

Makimoto A. Makimoto A. Cancers (Basel). 2022 May 2;14(9):2270. doi: 10.3390/cancers14092270. Cancers (Basel). 2022. PMID: 35565399 Free PMC article. Review.

2

Development of a Selective Tumor-Targeted Drug Delivery System: Hydroxypropyl-Acrylamide Polymer-Conjugated Pirarubicin (P-THP) for Pediatric Solid Tumors.

Makimoto A, Fang J, Maeda H. Makimoto A, et al. Cancers (Basel). 2021 Jul 23;13(15):3698. doi: 10.3390/cancers13153698. Cancers (Basel). 2021. PMID: 34359599 Free PMC article. Review.

3

Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects.

Makimoto A, Fujisaki H, Matsumoto K, Takahashi Y, Cho Y, Morikawa Y, Yuza Y, Tajiri T, Iehara T. Makimoto A, et al. Cancers (Basel). 2024 Jan 26;16(3):544. doi: 10.3390/cancers16030544. Cancers (Basel). 2024. PMID: 38339295 Free PMC article. Review.

4

Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective.

Hayashi H, Makimoto A, Yuza Y. Hayashi H, et al. Among authors: makimoto a. Cancers (Basel). 2024 Feb 8;16(4):723. doi: 10.3390/cancers16040723. Cancers (Basel). 2024. PMID: 38398113 Free PMC article. Review.

5

Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy.

Kojima Y, Hashimoto K, Ando M, Yonemori K, Hirakawa A, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Kojima Y, et al. Among authors: makimoto a. J Cancer Res Clin Oncol. 2012 Jul;138(7):1249-57. doi: 10.1007/s00432-012-1199-x. Epub 2012 Mar 23. J Cancer Res Clin Oncol. 2012. PMID: 22441933

6

Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.

Kajita N, Saito Y, Makimoto A, Miyahara S, Yuza Y. Kajita N, et al. Among authors: makimoto a. Pediatr Int. 2020 Jun;62(6):742-744. doi: 10.1111/ped.14172. Epub 2020 Jun 4. Pediatr Int. 2020. PMID: 32495974 No abstract available.

7

Tumor-Treating Fields Therapy for Pediatric Brain Tumors.

Makimoto A, Nishikawa R, Terashima K, Kurihara J, Fujisaki H, Ihara S, Morikawa Y, Yuza Y. Makimoto A, et al. Neurol Int. 2021 Apr 8;13(2):151-165. doi: 10.3390/neurolint13020015. Neurol Int. 2021. PMID: 33917660 Free PMC article. Review.

8

Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.

Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y. Kojima Y, et al. Among authors: makimoto a. Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7. doi: 10.1007/s00280-012-1920-0. Epub 2012 Jul 18. Cancer Chemother Pharmacol. 2012. PMID: 22806306

9

Registration-directed phase 1/2 trial of irinotecan for pediatric solid tumors.

Makimoto A, Mugishima H, Taga T, Ishida Y, Nagatoshi Y, Ida K, Kumagai M, Kimura T, Ohashi Y, Kaneko M. Makimoto A, et al. Pediatr Int. 2019 May;61(5):453-458. doi: 10.1111/ped.13826. Epub 2019 May 14. Pediatr Int. 2019. PMID: 30859690 Clinical Trial.

10

Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial.

Makimoto A, Matsui M, Chin M, Koh K, Tomotsune M, Kaneko T, Morikawa Y, Yuza Y. Makimoto A, et al. Contemp Clin Trials Commun. 2019 Aug 22;16:100440. doi: 10.1016/j.conctc.2019.100440. eCollection 2019 Dec. Contemp Clin Trials Commun. 2019. PMID: 31508533 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

104 results

Search Page